Southern Archipelago (A33) H2 2023 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2023 earnings summary
5 Nov, 2026Executive summary
FY2023 revenue rose to S$5.20m from S$4.84m; net profit was S$44,433 versus a S$488,906 loss in FY2022. Sterilisation remained the main revenue and profit contributor.
A proposed hospitality and wellness asset acquisition was aborted on 29 December 2023; management is reassessing plans and continuing to explore other opportunities.
Financial highlights
Revenue was S$5.196m versus S$4.837m; profit before tax was S$587,258 versus S$64,787, and net profit was S$44,433 versus a S$488,906 loss.
Total expenses decreased to S$5.125m from S$7.220m; other gains fell to S$463,377 from S$2.352m, which included a prior-year S$1.809m gain on disposal of an asset held for sale.
Total comprehensive loss narrowed to S$366,869 from S$811,288, reflecting S$411,302 of other comprehensive loss in FY2023.
Operating cash flow was S$1.065m; investing cash outflow was S$1.254m and financing cash outflow was S$4.044m. Year-end cash was S$3.080m versus S$7.343m.
Outlook and guidance
Management expects the sterilisation business to perform well and generate positive operating cash flows over the next 12 months; PT Rel-ion is expected to remain a sizeable revenue contributor in FY2024.
Hospitality and wellness remains a targeted diversification area; management plans to seek new opportunities while reassessing its aborted acquisition plans.
Fundraising options under consideration include bank loans, shareholder loans or extensions, subsidiary loans and shareholder fundraising to support working capital as needed.
Latest events from Southern Archipelago
- Sterilisation recovery continues, but liquidity strains and a covenant breach cloud the outlook.A33
Q3 2026 - A return to modest profit meets weaker revenue and widening working-capital pressure.A33
H1 2024 - Sterilisation expansion continued as lower revenue, a net loss and tight liquidity shaped FY2024.A33
H2 2024 - Sterilisation growth plans amid a S$566k loss, negative working capital and covenant risk.A33
H1 2025 - Revenue fell 17.8%; upgraded capacity meets a strained balance sheet and recovery test.A33
H2 2025 - Revenue fell 47% amid Indonesian headwinds, with liquidity and covenant risks still acute.A33
Q1 2026 - Sterilisation rebounded in 2Q, but liquidity pressure and a loan covenant breach persist.A33
H1 2026